,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of voting stock held by non affiliates of the registrant as of June 30, 2020 was $281,771,756,077 (based on the last reported sale price of $294.95 per share on June 30, 2020, on the New York Stock Exchange), excluding only shares of voting stock held beneficially by directors, executive officers and subsidiaries of the registrant.","281,771,756,077",['Public Float'],dei_EntityPublicFloat,monetaryItemType,unh,"The aggregate market value of voting stock held by non affiliates of the registrant as of June 30, 2020 was $281,771,756,077 (based on the last reported sale price of $294.95 per share on June 30, 2020, on the New York Stock Exchange), excluding only shares of voting stock held beneficially by directors, executive officers and subsidiaries of the registrant.","$281,771,756,077",MONEY,"The aggregate market value of voting stock held by non affiliates of the registrant as of June 30, 2020 was $281,771,756,077 based on the last reported sale price of $294.95 per share on June 30, 2020, on the New York Stock Exchange, excluding only shares of voting stock held beneficially by directors, executive officers and subsidiaries of the registrant.","['aggregate market value', 'non affiliates of registrant', 'last reported sale price', 'only shares', 'executive officers of registrant', 'aggregate market value', 'non affiliates', 'last sale price', 'only shares']","['aggregate market value', 0.7643893957138062, 'what is aggregate market value ?', '$281,771,756,077']",aggregate market value,0.7643893957138062,what is aggregate market value ?,"$281,771,756,077",Aggregate market value of voting stock held by non affiliates
1,"As of January 29, 2021, there were 945,319,404 shares of the registrant's Common Stock, $.01 par value per share, issued and outstanding.","945,319,404","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,unh,"As of January 29, 2021, there were 945,319,404 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.","945,319,404",CARDINAL,"As of January 29, 2021, there were 945,319,404 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.","['shares of registrant ’s of Common Stock', '.01 par value per share', 'registrant ’s', 'Common Stock']","['registrant ’s', 0.9625512361526489, 'how many registrant ’s ?', '945,319,404']",registrant ’s,0.9625512361526488,how many registrant ’s ?,"945,319,404",the registrant's Common Stock
2,"As of December 31, 2020, we had $2.3 billion of investments in equity securities, primarily consisting of investments in employee savings plan related investments and non U.S. dollar fixed income funds. Valuations in non U.S. dollar funds are subject to foreign exchange rates.",2.3,"['Equity Securities, FV NI and without Readily Determinable Fair Value']",us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue,monetaryItemType,unh,"As of December 31, 2020, we had $2.3 billion of investments in equity securities, primarily consisting of investments in employee savings plan related investments and non U.S. dollar fixed income funds.",$2.3 billion,MONEY,"As of December 31, 2020, we had $2.3 billion of investments in equity securities, primarily consisting of investments in employee savings plan related investments and non U.S. dollar fixed income funds.","['investments in equity securities', 'investments in savings plan', 'equity securities', 'savings plan']","['investments in equity securities', 0.5492802858352661, 'What is $2.3 billion ?', 'investments in equity securities']",investments in equity securities,0.5492802858352661,What is $2.3 billion ?,investments in equity securities,Investments in equity securities
3,"Property, equipment and capitalized software, net of accumulated depreciation and amortization of $5,230 and $4,995","5,230","['Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment']",us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,monetaryItemType,unh,"Property, equipment and capitalized software, net of accumulated depreciation and amortization of $5,230 and $4,995","$5,230",MONEY,"Property, equipment and capitalized software, net of accumulated depreciation and amortization of $5,230 and $4,995","['net of accumulated depreciation', 'accumulated depreciation']","['amortization', 0.8846348524093628, 'What is $5,230 ?', 'amortization']",amortization,0.8846348524093628,"What is $5,230 ?",amortization,"Accumulated depreciation

Entity:
$4,995
Phrase:
Amortization"
4,"Property, equipment and capitalized software, net of accumulated depreciation and amortization of $5,230 and $4,995","4,995","['Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment']",us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,monetaryItemType,unh,"Property, equipment and capitalized software, net of accumulated depreciation and amortization of $5,230 and $4,995","$4,995",MONEY,"Property, equipment and capitalized software, net of accumulated depreciation and amortization of $5,230 and $4,995","['net of accumulated depreciation', 'accumulated depreciation']","['net of accumulated depreciation', 0.599216878414154, 'what is net of accumulated depreciation ?', '$5,230 and $4,995']",net of accumulated depreciation,0.599216878414154,what is net of accumulated depreciation ?,"$5,230 and $4,995",Capitalized software depreciation and amortization
5,"Other intangible assets, net of accumulated amortization of $5,455 and $5,072","5,455","['Finite lived Intangible Assets, Accumulated Amortization']",us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization,monetaryItemType,unh,"Other intangible assets, net of accumulated amortization of $5,455 and $5,072","$5,455",MONEY,"Other intangible assets, net of accumulated amortization of $5,455 and $5,072","['net of accumulated amortization', 'accumulated amortization']","['accumulated amortization', 0.7901525497436523, 'What is $5,455 ?', 'accumulated amortization']",accumulated amortization,0.7901525497436523,"What is $5,455 ?",accumulated amortization,"Intangible assets, net of accumulated amortization"
6,"Other intangible assets, net of accumulated amortization of $5,455 and $5,072","5,072","['Finite lived Intangible Assets, Accumulated Amortization']",us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization,monetaryItemType,unh,"Other intangible assets, net of accumulated amortization of $5,455 and $5,072","$5,072",MONEY,"Other intangible assets, net of accumulated amortization of $5,455 and $5,072","['net of accumulated amortization', 'accumulated amortization']","['accumulated amortization', 0.2181503176689148, 'What is $5,072 ?', 'accumulated amortization']",accumulated amortization,0.2181503176689148,"What is $5,072 ?",accumulated amortization,"Intangible assets, net of accumulated amortization"
7,"Preferred stock, $0.001 par value 10 shares authorized; no shares issued or outstanding",10,"['Preferred stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,unh,"Preferred stock, $0.001 par value   10 shares authorized; no shares issued or outstanding",10,CARDINAL,"Preferred stock, $0.001 par value   10 shares authorized; no shares issued or outstanding",[],"['shares authorized', 0.908186137676239, 'What is 10 ?', 'shares authorized']",shares authorized,0.908186137676239,What is 10 ?,shares authorized,Preferred stock authorized
8,"Preferred stock, $0.001 par value 10 shares authorized; no shares issued or outstanding",10,"['Preferred stock, shares authorized']",us-gaap_PreferredStockSharesAuthorized,sharesItemType,unh,"Preferred stock, $0.001 par value   10 shares authorized; no shares issued or outstanding",10,CARDINAL,"Preferred stock, $0.001 par value   10 shares authorized; no shares issued or outstanding",[],"['shares authorized', 0.908186137676239, 'What is 10 ?', 'shares authorized']",shares authorized,0.908186137676239,What is 10 ?,shares authorized,Preferred stock shares authorized
9,"Common stock, $0.01 par value 3,000 shares authorized; 946 and 948 issued and outstanding","3,000","['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,unh,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding","3,000",CARDINAL,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",['Common stock'],"['Common stock', 0.9348530769348145, 'how many Common stock ?', '3,000']",Common stock,0.9348530769348145,how many Common stock ?,"3,000",shares authorized
10,"Common stock, $0.01 par value 3,000 shares authorized; 946 and 948 issued and outstanding","3,000","['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,unh,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding","3,000",CARDINAL,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",['Common stock'],"['Common stock', 0.9348530769348145, 'how many Common stock ?', '3,000']",Common stock,0.9348530769348145,how many Common stock ?,"3,000",Common stock shares authorized
11,"Common stock, $0.01 par value 3,000 shares authorized; 946 and 948 issued and outstanding",946,"['Common stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,unh,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",946,CARDINAL,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",['Common stock'],"['issued and outstanding', 0.7252424359321594, 'What is 946 ?', 'issued and outstanding']",issued and outstanding,0.7252424359321594,What is 946 ?,issued and outstanding,"shares authorized

Entity:
948
Phrase:
shares authorized"
12,"Common stock, $0.01 par value 3,000 shares authorized; 946 and 948 issued and outstanding",946,"['Common Stock, Shares, Outstanding', 'Common Stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,unh,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",946,CARDINAL,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",['Common stock'],"['issued and outstanding', 0.7252424359321594, 'What is 946 ?', 'issued and outstanding']",issued and outstanding,0.7252424359321594,What is 946 ?,issued and outstanding,"shares authorized

Entity:
948
Phrase:
 shares authorized"
13,"Common stock, $0.01 par value 3,000 shares authorized; 946 and 948 issued and outstanding",948,"['Common Stock, Shares, Outstanding', 'Common Stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,unh,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",948,CARDINAL,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",['Common stock'],"['issued and outstanding', 0.8954241275787354, 'What is 948 ?', 'issued and outstanding']",issued and outstanding,0.8954241275787354,What is 948 ?,issued and outstanding,shares authorized
14,"Common stock, $0.01 par value 3,000 shares authorized; 946 and 948 issued and outstanding",948,"['Common stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,unh,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",948,CARDINAL,"Common stock, $0.01 par value   3,000 shares authorized; 946 and 948 issued and outstanding",['Common stock'],"['issued and outstanding', 0.8954241275787354, 'What is 948 ?', 'issued and outstanding']",issued and outstanding,0.8954241275787354,What is 948 ?,issued and outstanding,shares outstanding
15,"As of December 31, 2020 and 2019, accounts receivables related to products and services were $5.3 billion and $4.3 billion, respectively. In 2020 and 2019, the Company had no material bad debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2020 or 2019.",5.3,"['Accounts Receivable, after Allowance for Credit Loss, Current', 'Accounts receivable, net of allowances of $990 and $519']",us-gaap_AccountsReceivableNetCurrent,monetaryItemType,unh,"As of December 31, 2020 and 2019, accounts receivables related to products and services were $5.3 billion and $4.3 billion, respectively.",$5.3 billion,MONEY,"As of December 31, 2020 and 2019, accounts receivables related to products and services were $5.3 billion and $4.3 billion, respectively.",[],"['accounts receivables related to products and services', 0.6158061027526855, 'What is $5.3 billion ?', 'accounts receivables related to products and services']",accounts receivables related to products and services,0.6158061027526855,What is $5.3 billion ?,accounts receivables related to products and services,accounts receivables related to products and services
16,"As of December 31, 2020 and 2019, accounts receivables related to products and services were $5.3 billion and $4.3 billion, respectively. In 2020 and 2019, the Company had no material bad debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2020 or 2019.",4.3,"['Accounts Receivable, after Allowance for Credit Loss, Current', 'Accounts receivable, net of allowances of $990 and $519']",us-gaap_AccountsReceivableNetCurrent,monetaryItemType,unh,"As of December 31, 2020 and 2019, accounts receivables related to products and services were $5.3 billion and $4.3 billion, respectively.",$4.3 billion,MONEY,"As of December 31, 2020 and 2019, accounts receivables related to products and services were $5.3 billion and $4.3 billion, respectively.",[],"['accounts receivables related to products and services', 0.577894389629364, 'What is $4.3 billion ?', 'accounts receivables related to products and services']",accounts receivables related to products and services,0.577894389629364,What is $4.3 billion ?,accounts receivables related to products and services,accounts receivables related to products and services
17,"The Company's pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers' products by its affiliated and non affiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2020 and 2019, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $6.3 billion and $4.7 billion, respectively.",6.3,"['Other current receivables', 'Other current receivables, net of allowances of $1,047 and $859']",us-gaap_OtherReceivablesNetCurrent,monetaryItemType,unh,"As of December 31, 2020 and 2019, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $6.3 billion and $4.7 billion, respectively.",$6.3 billion,MONEY,"As of December 31, 2020 and 2019, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $6.3 billion and $4.7 billion, respectively.","['other receivables in Consolidated Balance Sheets', 'total pharmaceutical manufacturer', 'other receivables']","['other receivables in Consolidated Balance Sheets', 0.4303804039955139, 'what is other receivables in Consolidated Balance Sheets ?', '$6.3 billion and $4.7 billion']",other receivables in Consolidated Balance Sheets,0.4303804039955139,what is other receivables in Consolidated Balance Sheets ?,$6.3 billion and $4.7 billion,Total pharmaceutical manufacturer rebates receivable
18,"The Company's pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers' products by its affiliated and non affiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2020 and 2019, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $6.3 billion and $4.7 billion, respectively.",4.7,"['Other current receivables', 'Other current receivables, net of allowances of $1,047 and $859']",us-gaap_OtherReceivablesNetCurrent,monetaryItemType,unh,"As of December 31, 2020 and 2019, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $6.3 billion and $4.7 billion, respectively.",$4.7 billion,MONEY,"As of December 31, 2020 and 2019, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $6.3 billion and $4.7 billion, respectively.","['other receivables in Consolidated Balance Sheets', 'total pharmaceutical manufacturer', 'other receivables']","['other receivables in Consolidated Balance Sheets', 0.4303804039955139, 'what is other receivables in Consolidated Balance Sheets ?', '$6.3 billion and $4.7 billion']",other receivables in Consolidated Balance Sheets,0.4303804039955139,what is other receivables in Consolidated Balance Sheets ?,$6.3 billion and $4.7 billion,Total pharmaceutical manufacturer rebates receivable
19,"As of December 31, 2020 and 2019, the Company's Medicare Part D receivables amounted to $2.9 billion and $2.3 billion, respectively.",2.9,"['Other current receivables', 'Other current receivables, net of allowances of $1,047 and $859']",us-gaap_OtherReceivablesNetCurrent,monetaryItemType,unh,"As of December 31, 2020 and 2019, the Company’s Medicare Part D receivables amounted to $2.9 billion and $2.3 billion, respectively.",$2.9 billion,MONEY,"As of December 31, 2020 and 2019, the Company’s Medicare Part D receivables amounted to $2.9 billion and $2.3 billion, respectively.",['D receivables'],"['', 0, '', '']",,0.0,,,the Company's Medicare Part D receivables
20,"As of December 31, 2020 and 2019, the Company's Medicare Part D receivables amounted to $2.9 billion and $2.3 billion, respectively.",2.3,"['Other current receivables', 'Other current receivables, net of allowances of $1,047 and $859']",us-gaap_OtherReceivablesNetCurrent,monetaryItemType,unh,"As of December 31, 2020 and 2019, the Company’s Medicare Part D receivables amounted to $2.9 billion and $2.3 billion, respectively.",$2.3 billion,MONEY,"As of December 31, 2020 and 2019, the Company’s Medicare Part D receivables amounted to $2.9 billion and $2.3 billion, respectively.",['D receivables'],"['', 0, '', '']",,0.0,,,the Company's Medicare Part D receivables
21,"Other current liabilities include health savings account deposits ($10.2 billion and $8.3 billion as of December 31, 2020 and 2019, respectively), the RSF associated with the AARP Program, accruals for premium rebates payable, the current portion of future policy benefits and customer balances.",10.2,['Health savings account deposits'],us-gaap_DemandDepositAccounts,monetaryItemType,unh,"Other current liabilities include health savings account deposits ($10.2 billion and $8.3 billion as of December 31, 2020 and 2019, respectively), the RSF associated with the AARP Program, accruals for premium rebates payable, the current portion of future policy benefits and customer balances.",$10.2 billion,MONEY,"Other current liabilities include health savings account deposits $10.2 billion and $8.3 billion as of December 31, 2020 and 2019, respectively, the RSF associated with the AARP Program, accruals for premium rebates payable, the current portion of future policy benefits and customer balances.","['accruals for premium rebates', 'current portion of future policy benefits', 'Other current liabilities', 'savings account', 'premium rebates', 'future policy benefits']","['health savings account deposits', 0.667157769203186, 'What is $10.2 billion ?', 'health savings account deposits']",health savings account deposits,0.667157769203186,What is $10.2 billion ?,health savings account deposits,"health savings account deposits

Entity:
$8.3 billion
Phrase:
accruals for premium rebates payable"
22,"Other current liabilities include health savings account deposits ($10.2 billion and $8.3 billion as of December 31, 2020 and 2019, respectively), the RSF associated with the AARP Program, accruals for premium rebates payable, the current portion of future policy benefits and customer balances.",8.3,['Health savings account deposits'],us-gaap_DemandDepositAccounts,monetaryItemType,unh,"Other current liabilities include health savings account deposits ($10.2 billion and $8.3 billion as of December 31, 2020 and 2019, respectively), the RSF associated with the AARP Program, accruals for premium rebates payable, the current portion of future policy benefits and customer balances.",$8.3 billion,MONEY,"Other current liabilities include health savings account deposits $10.2 billion and $8.3 billion as of December 31, 2020 and 2019, respectively, the RSF associated with the AARP Program, accruals for premium rebates payable, the current portion of future policy benefits and customer balances.","['accruals for premium rebates', 'current portion of future policy benefits', 'Other current liabilities', 'savings account', 'premium rebates', 'future policy benefits']","['health savings account deposits', 0.4010583162307739, 'What is $8.3 billion ?', 'health savings account deposits']",health savings account deposits,0.4010583162307739,What is $8.3 billion ?,health savings account deposits,Current portion of future policy benefits
23,"The ACA included an annual, nondeductible insurance industry tax (Health Insurance Industry Tax) to be levied proportionally across the insurance industry for risk based health insurance products. After a moratorium in 2019, the industry wide amount of the Health Insurance Industry Tax for 2020, which was primarily borne by the customer, was $15.5 billion, of which the Company's portion was approximately $3.0 billion. The Health Insurance Industry Tax was permanently repealed by Congress, effective January 1, 2021.",3.0,['Health Insurance Industry Tax'],us-gaap_InsuranceTax,monetaryItemType,unh,"After a moratorium in 2019, the industry wide amount of the Health Insurance Industry Tax for 2020, which was primarily borne by the customer, was $15.5 billion, of which the Company’s portion was approximately $3.0 billion.",approximately $3.0 billion,MONEY,"After a moratorium in 2019, the industry wide amount of the Health Insurance Industry Tax for 2020, which was primarily borne by the customer, was $15.5 billion, of which the Company’s portion was approximately $3.0 billion.","['moratorium', 'wide amount of Industry Tax', 'wide amount', 'wide amount']","['the Company’s portion', 0.641148030757904, 'What is approximately $3.0 billion ?', 'the Company’s portion']",the Company’s portion,0.641148030757904,What is approximately $3.0 billion ?,the Company’s portion,Health Insurance Industry Tax
24,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively. The Company's investments in equity securities primarily consist of employee savings plan related investments and shares of Brazilian real denominated fixed income funds with readily determinable fair values. Additionally, the Company's investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the",2.3,"['Equity Securities, FV NI and without Readily Determinable Fair Value']",us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue,monetaryItemType,unh,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively.",$2.3 billion,MONEY,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively.",['equity securities'],"['equity securities', 0.9668883681297302, 'What is $2.3 billion ?', 'equity securities']",equity securities,0.9668883681297302,What is $2.3 billion ?,equity securities,"Held equity securities

Entity: 
$2.0 billion
Phrase: 
Held equity securities"
25,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively. The Company's investments in equity securities primarily consist of employee savings plan related investments and shares of Brazilian real denominated fixed income funds with readily determinable fair values. Additionally, the Company's investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the",2.0,"['Equity Securities, FV NI and without Readily Determinable Fair Value']",us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue,monetaryItemType,unh,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively.",$2.0 billion,MONEY,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively.",['equity securities'],"['equity securities', 0.9924343228340149, 'What is $2.0 billion ?', 'equity securities']",equity securities,0.9924343228340148,What is $2.0 billion ?,equity securities,Held equity securities
26,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively. The Company's investments in equity securities primarily consist of employee savings plan related investments and shares of Brazilian real denominated fixed income funds with readily determinable fair values. Additionally, the Company's investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the",1.3,['Equity Method Investments'],us-gaap_EquityMethodInvestments,monetaryItemType,unh,"Additionally, the Company’s investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the",$1.3 billion,MONEY,"Additionally, the Company’s investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the","['operating businesses', 'method investments']","['equity method investments', 0.4585219919681549, 'What is $1.3 billion ?', 'equity method investments']",equity method investments,0.4585219919681549,What is $1.3 billion ?,equity method investments,Equity method investments in operating businesses
27,"The Company held $2.3 billion and $2.0 billion of equity securities as of December 31, 2020 and December 31, 2019, respectively. The Company's investments in equity securities primarily consist of employee savings plan related investments and shares of Brazilian real denominated fixed income funds with readily determinable fair values. Additionally, the Company's investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the",1.4,['Equity Method Investments'],us-gaap_EquityMethodInvestments,monetaryItemType,unh,"Additionally, the Company’s investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the",$1.4 billion,MONEY,"Additionally, the Company’s investments included $1.3 billion and $1.4 billion of equity method investments in operating businesses in the","['operating businesses', 'method investments']","['equity method investments', 0.44118326902389526, 'What is $1.4 billion ?', 'equity method investments']",equity method investments,0.4411832690238952,What is $1.4 billion ?,equity method investments,Equity method investments
28,"The Company's unrealized losses from all securities as of December 31, 2020 were generated from approximately 2,000 positions out of a total of 36,000 positions. The Company believes it will collect the timely principal and interest due on its debt securities having an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company's assessment on collectability of principal and interest. At each reporting period, the Company evaluates available for sale debt securities for any credit related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, and the potential economic impacts of COVID 19 on the issuers, noting no significant credit deterioration since purchase. As of December 31, 2020, the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available for sale debt securities at December 31, 2020 was not material.","2,000","['Available for sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions']",us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1,integerItemType,unh,"The Company’s unrealized losses from all securities as of December 31, 2020 were generated from approximately 2,000 positions out of a total of 36,000 positions.","approximately 2,000",CARDINAL,"The Company’s unrealized losses from all securities as of December 31, 2020 were generated from approximately 2,000 positions out of a total of 36,000 positions.","['unrealized losses from securities', 'unrealized losses', 'total of positions', 'unrealized losses']","['', 0, '', '']",,0.0,,,unrealized losses from all securities
29,"Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively. Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",997,['Depreciation'],us-gaap_Depreciation,monetaryItemType,unh," Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively.",$997 million,MONEY," Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively.","['Depreciation expense for property', 'Depreciation expense for years', 'Depreciation expense']","['Depreciation expense', 0.6472200751304626, 'What is $997 million ?', 'Depreciation expense']",Depreciation expense,0.6472200751304626,What is $997 million ?,Depreciation expense,Depreciation expense for property and equipment
30,"Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively. Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",995,['Depreciation'],us-gaap_Depreciation,monetaryItemType,unh," Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively.",$995 million,MONEY," Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively.","['Depreciation expense for property', 'Depreciation expense for years', 'Depreciation expense']","['Depreciation expense', 0.4526909291744232, 'What is $995 million ?', 'Depreciation expense']",Depreciation expense,0.4526909291744232,What is $995 million ?,Depreciation expense,Depreciation expense for property and equipment
31,"Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively. Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",924,['Depreciation'],us-gaap_Depreciation,monetaryItemType,unh," Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively.",$924 million,MONEY," Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively.","['Depreciation expense for property', 'Depreciation expense for years', 'Depreciation expense']","['', 0, '', '']",,0.0,,,Depreciation expense for property and equipment
32,"Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively. Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",814,"['Capitalized Computer Software, Amortization']",us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,unh,"Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",$814 million,MONEY,"Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.","['Amortization expense for capitalized software', 'Amortization expense for years', 'Amortization expense']","['Amortization expense for capitalized software', 0.5009221434593201, 'What is $814 million ?', 'Amortization expense for capitalized software']",Amortization expense for capitalized software,0.5009221434593201,What is $814 million ?,Amortization expense for capitalized software,Amortization expense for capitalized software
33,"Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively. Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",721,"['Capitalized Computer Software, Amortization']",us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,unh,"Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",$721 million and,MONEY,"Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.","['Amortization expense for capitalized software', 'Amortization expense for years', 'Amortization expense']","['', 0, '', '']",,0.0,,,amortization expense for capitalized software
34,"Depreciation expense for property and equipment for the years ended December 31, 2020, 2019 and 2018 was $997 million, $995 million and $924 million, respectively. Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",606,"['Capitalized Computer Software, Amortization']",us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,unh,"Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.",$606 million,MONEY,"Amortization expense for capitalized software for the years ended December 31, 2020, 2019 and 2018 was $814 million, $721 million and $606 million, respectively.","['Amortization expense for capitalized software', 'Amortization expense for years', 'Amortization expense']","['$721 million', 0.783010721206665, 'What is $606 million ?', '$721 million']",$721 million,0.783010721206665,What is $606 million ?,$721 million,Amortization expense for capitalized software
35,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.",1.1,['Amortization of Intangible Assets'],us-gaap_AmortizationOfIntangibleAssets,monetaryItemType,unh,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.",$1.1 billion,MONEY,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.","['Amortization expense', 'intangible assets']","['Amortization expense relating to intangible assets', 0.3540304899215698, 'What is $1.1 billion ?', 'Amortization expense relating to intangible assets']",Amortization expense relating to intangible assets,0.3540304899215698,What is $1.1 billion ?,Amortization expense relating to intangible assets,"Amortization expense relating to intangible assets

Entity: 
$1.0 billion
Phrase: 
Amortization expense relating to intangible assets

Entity: 
$898 million
Phrase: 
Amortization expense relating to intangible assets"
36,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.",1.0,['Amortization of Intangible Assets'],us-gaap_AmortizationOfIntangibleAssets,monetaryItemType,unh,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.",$1.0 billion,MONEY,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.","['Amortization expense', 'intangible assets']","['Amortization expense relating to intangible assets', 0.21857093274593353, 'What is $1.0 billion ?', 'Amortization expense relating to intangible assets']",Amortization expense relating to intangible assets,0.2185709327459335,What is $1.0 billion ?,Amortization expense relating to intangible assets,Amortization expense relating to intangible assets
37,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.",898,['Amortization of Intangible Assets'],us-gaap_AmortizationOfIntangibleAssets,monetaryItemType,unh,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.",$898 million,MONEY,"Amortization expense relating to intangible assets for the years ended December 31, 2020, 2019 and 2018 was $1.1 billion, $1.0 billion and $898 million, respectively.","['Amortization expense', 'intangible assets']","['intangible assets', 0.13461215794086456, 'what is intangible assets ?', '$1.0 billion and $898 million']",intangible assets,0.1346121579408645,what is intangible assets ?,$1.0 billion and $898 million,Amortization expense relating to intangible assets
38,"For the years ended December 31, 2020 and 2019 medical cost reserve development was primarily driven by lower than expected health system utilization levels. For the year ended December 31, 2018, no individual factors significantly impacted medical cost reserve development. Medical costs payable included IBNR of $14.8 billion and $13.8 billion at December 31, 2020 and 2019, respectively. Substantially all of the IBNR balance as of December 31, 2020 relates to the current year.",14.8,"['Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported  Claims, Amount']",us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount,monetaryItemType,unh,"Medical costs payable included IBNR of $14.8 billion and $13.8 billion at December 31, 2020 and 2019, respectively.",$14.8 billion,MONEY,"Medical costs payable included IBNR of $14.8 billion and $13.8 billion at December 31, 2020 and 2019, respectively.",['Medical payable costs'],"['Medical payable costs', 0.7338769435882568, 'what is Medical payable costs ?', '$14.8 billion']",Medical payable costs,0.7338769435882568,what is Medical payable costs ?,$14.8 billion,IBNR medical costs payable
39,"For the years ended December 31, 2020 and 2019 medical cost reserve development was primarily driven by lower than expected health system utilization levels. For the year ended December 31, 2018, no individual factors significantly impacted medical cost reserve development. Medical costs payable included IBNR of $14.8 billion and $13.8 billion at December 31, 2020 and 2019, respectively. Substantially all of the IBNR balance as of December 31, 2020 relates to the current year.",13.8,"['Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported  Claims, Amount']",us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount,monetaryItemType,unh,"Medical costs payable included IBNR of $14.8 billion and $13.8 billion at December 31, 2020 and 2019, respectively.",$13.8 billion,MONEY,"Medical costs payable included IBNR of $14.8 billion and $13.8 billion at December 31, 2020 and 2019, respectively.",['Medical payable costs'],"['IBNR', 0.3428352177143097, 'What is $13.8 billion ?', 'IBNR']",IBNR,0.3428352177143097,What is $13.8 billion ?,IBNR,Medical costs payable IBNR
40,"The Company's long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",1.2,['Other Long term Debt'],us-gaap_OtherLongTermDebt,monetaryItemType,unh,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",$1.2 billion,MONEY,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.","['term debt obligations', 'other financing obligations']","['other financing obligations', 0.39244285225868225, 'what is other financing obligations ?', 'long term debt obligations also included $1.2 billion']",other financing obligations,0.3924428522586822,what is other financing obligations ?,long term debt obligations also included $1.2 billion,The Company's long term debt obligations
41,"The Company's long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",1.2,['Other Long term Debt'],us-gaap_OtherLongTermDebt,monetaryItemType,unh,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",$1.2 billion,MONEY,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.","['term debt obligations', 'other financing obligations']","['other financing obligations', 0.39244285225868225, 'what is other financing obligations ?', 'long term debt obligations also included $1.2 billion']",other financing obligations,0.3924428522586822,what is other financing obligations ?,long term debt obligations also included $1.2 billion,The Company's long term debt obligations
42,"The Company's long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",354,"['Other Long term Debt, Current']",us-gaap_OtherLongTermDebtCurrent,monetaryItemType,unh,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",$354 million,MONEY,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.","['term debt obligations', 'other financing obligations']","['', 0, '', '']",,0.0,,,Long term debt obligations
43,"The Company's long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",322,"['Other Long term Debt, Current']",us-gaap_OtherLongTermDebtCurrent,monetaryItemType,unh,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.",$322 million,MONEY,"The Company’s long term debt obligations also included $1.2 billion of other financing obligations as of both December 31, 2020 and 2019, of which $354 million and $322 million were current as of December 31, 2020 and 2019, respectively.","['term debt obligations', 'other financing obligations']","['', 0, '', '']",,0.0,,,Other financing obligations
44,"Commercial paper consists of short duration, senior unsecured debt privately placed on a discount basis through broker dealers. As of December 31, 2020, the Company's outstanding commercial paper had a weighted average annual interest rate of 0.2%.",0.2,"['Debt Instrument, Interest Rate, Effective Percentage']",us-gaap_DebtInstrumentInterestRateEffectivePercentage,percentItemType,unh,"As of December 31, 2020, the Company’s outstanding commercial paper had a weighted average annual interest rate of 0.2%.",0.2%,PERCENT,"As of December 31, 2020, the Company’s outstanding commercial paper had a weighted average annual interest rate of 0.2%.","['weighted average annual interest rate of %', 'outstanding commercial paper', 'weighted average annual interest rate']","['weighted average annual interest rate', 0.9849110245704651, 'what is weighted average annual interest rate ?', '0.2%']",weighted average annual interest rate,0.9849110245704652,what is weighted average annual interest rate ?,0.2%,Interest rate on commercial paper
45,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively. These facilities provide full liquidity support for the Company's commercial paper program and are available for general corporate purposes. As of December 31, 2020, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company's senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.",4.4,"['Line of Credit, Credit Facility, Maximum Borrowing Capacity']",us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity,monetaryItemType,unh,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively.",$4.4 billion,MONEY,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively.","['bank credit facilities with banks', 'bank credit facilities']","['', 0, '', '']",,0.0,,,"Five year bank credit facilities

Entity: 
$4.4 billion
Phrase: 
Three year bank credit facilities

Entity: 
$3.8 billion
Phrase: 
364 day revolving bank credit facilities"
46,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively. These facilities provide full liquidity support for the Company's commercial paper program and are available for general corporate purposes. As of December 31, 2020, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company's senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.",4.4,"['Line of Credit, Credit Facility, Maximum Borrowing Capacity']",us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity,monetaryItemType,unh,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively.",$4.4 billion,MONEY,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively.","['bank credit facilities with banks', 'bank credit facilities']","['', 0, '', '']",,0.0,,,"five year bank credit facilities

Entity:
$4.4 billion
Phrase:
three year bank credit facilities

Entity:
$3.8 billion
Phrase:
364 day revolving bank credit facilities"
47,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively. These facilities provide full liquidity support for the Company's commercial paper program and are available for general corporate purposes. As of December 31, 2020, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company's senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.",3.8,"['Line of Credit, Credit Facility, Maximum Borrowing Capacity']",us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity,monetaryItemType,unh,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively.",$3.8 billion,MONEY,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively.","['bank credit facilities with banks', 'bank credit facilities']","['', 0, '', '']",,0.0,,,364 day revolving bank credit facilities
48,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively. These facilities provide full liquidity support for the Company's commercial paper program and are available for general corporate purposes. As of December 31, 2020, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company's senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.",0.8,"['Debt Instrument, Interest Rate During Period']",us-gaap_LineOfCreditFacilityInterestRateDuringPeriod,percentItemType,unh,"If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.",0.8% to 1.0%,PERCENT,"If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.","['bank credit facilities', 'annual interest rates']","['annual interest rates', 0.6650364995002747, 'what is annual interest rates ?', '0.8% to 1.0%']",annual interest rates,0.6650364995002747,what is annual interest rates ?,0.8% to 1.0%,Bank credit facilities interest rates
49,"The Company has $4.4 billion five year, $4.4 billion three year and $3.8 billion 364 day revolving bank credit facilities with 26 banks, which mature in December 2025, December 2023 and December 2021, respectively. These facilities provide full liquidity support for the Company's commercial paper program and are available for general corporate purposes. As of December 31, 2020, no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company's senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.",1.0,"['Debt Instrument, Interest Rate During Period']",us-gaap_LineOfCreditFacilityInterestRateDuringPeriod,percentItemType,unh,"If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.",0.8% to 1.0%,PERCENT,"If amounts had been drawn on the bank credit facilities as of December 31, 2020, annual interest rates would have ranged from 0.8% to 1.0%.","['bank credit facilities', 'annual interest rates']","['annual interest rates', 0.6650364995002747, 'what is annual interest rates ?', '0.8% to 1.0%']",annual interest rates,0.6650364995002747,what is annual interest rates ?,0.8% to 1.0%,Annual interest rates
